-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Aviptadil-acetate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1444827-29-5.gif)
| Category | SARS-CoV |
| CAS | 1444827-29-5 |
| Description | Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. It induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure. |
Product Information
| Synonyms | Aviptadil Acetate|Guinea pig VIP|Guinea pig VIP octacosapeptide|VIP, human, porcine, rat VIP (28 amino acids)|96886-24-7|AKOS034834067 |
| Molecular Weight | 3385.90 |
| Molecular Formula | C147H239N43O42S2 |
| Canonical SMILES | CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(C(C)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)N)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CNC=N4)N |
| Purity | ≥98% (HPLC) |
| Solubility | In Vitro: DMSO : 100 mg/mL(29.53 mM;Need ultrasonic) H2O : 100 mg/mL(29.53 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (0.74 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (0.74 mM); Suspended solution; Need ultrasonic 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (0.74 mM); Clear solution |
| Appearance | White to off-white (Solid) |
| Storage | Sealed storage, away from moisture and light Powder -80°C, 2 years -20°C, 1 years In solvent -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture and light) |
| Complexity | 7510 |
| Exact Mass | 3343.7362760 |
| In Vitro | Aviprodil acetate inhibits basal proliferation of pulmonary artery smooth muscle cells (PASMC) and mobilization of free calcium concentrations within these cells in a dose-dependent manner. Aviprodil acetate has a concentration-dependent inhibitory effect on CSE-induced L2 cell death. Aviprodil acetate (10nm-100 μM) attenuates MMP-9 activity induced by lipopolysaccharide (LPS)-induced rat alveolar macrophages (AM). |
| In Vivo | Aviprodil acetate (1, 3 and 10 mg/kg; intravenous bolus) injected into the tail vein. CD1 mice are inhaled by nasal inhalation nebulized inhalation. Aviprodil acetate at a dose of 1546 μg / kg / day is well tolerated and does not produce significant changes in any of the parameters evaluated. After a single administration of up to 3920 μg/kg/day, no changes were observed. |
| Target | SARS-CoV |
| XLogP3-AA | -13.7 |
